RU2001133669A - A way to limit complications and side effects in the treatment of tuberculosis - Google Patents

A way to limit complications and side effects in the treatment of tuberculosis

Info

Publication number
RU2001133669A
RU2001133669A RU2001133669/14A RU2001133669A RU2001133669A RU 2001133669 A RU2001133669 A RU 2001133669A RU 2001133669/14 A RU2001133669/14 A RU 2001133669/14A RU 2001133669 A RU2001133669 A RU 2001133669A RU 2001133669 A RU2001133669 A RU 2001133669A
Authority
RU
Russia
Prior art keywords
treatment
tuberculosis
side effects
way
pathogenetic
Prior art date
Application number
RU2001133669/14A
Other languages
Russian (ru)
Other versions
RU2217137C2 (en
Inventor
Владимир Михайлович Мудров
Лев Давидович Раснецов
Георгий Георгиевич Мордовской
Марина Николаевна Зуева
Original Assignee
Закрытое акционерное общество "Информационно-волновой центр "БИГ"
Filing date
Publication date
Application filed by Закрытое акционерное общество "Информационно-волновой центр "БИГ" filed Critical Закрытое акционерное общество "Информационно-волновой центр "БИГ"
Priority to RU2001133669/14A priority Critical patent/RU2217137C2/en
Priority claimed from RU2001133669/14A external-priority patent/RU2217137C2/en
Publication of RU2001133669A publication Critical patent/RU2001133669A/en
Application granted granted Critical
Publication of RU2217137C2 publication Critical patent/RU2217137C2/en

Links

Claims (4)

1. Способ ограничения осложнений и побочных явлений при лечении туберкулеза, включающий прием патогенетических средств в сочетании с препаратами группы гидразида изоникотиновой кислоты, отличающийся тем, что предварительно осуществляют прием патогенетического средства в терапевтических дозах, затем продолжают его прием в сочетании с препаратом группы гидразида изоникотиновой кислоты до конца лечения, а в качестве патогенетического средства используют препараты железа.1. A method of limiting complications and side effects in the treatment of tuberculosis, including the use of pathogenetic agents in combination with drugs of the isonicotinic acid hydrazide group, characterized in that the pathogenetic agent is first taken in therapeutic doses, then it is continued in combination with the drug of the isonicotinic acid hydrazide group until the end of treatment, and iron preparations are used as a pathogenetic agent. 2. Способ по п.1, отличающийся тем, что предварительный прием препаратов железа осуществляют в течение нескольких, по крайней мере, двух дней.2. The method according to claim 1, characterized in that the preliminary intake of iron preparations is carried out for several at least two days. 3. Способ по п.1 и 2, отличающийся тем, что в качестве препарата железа используют сульфат закиси железа.3. The method according to claim 1 and 2, characterized in that the iron oxide is ferrous sulfate. 4. Способ по пп.1-3, отличающийся тем, что при сочетанием приеме препаратов доза сульфата закиси железа, по крайней мере, в два раза больше дозы гидразида изоникотиновой кислоты.4. The method according to claims 1 to 3, characterized in that when the combination of drugs is taken, the dose of ferrous sulfate is at least twice the dose of isonicotinic acid hydrazide.
RU2001133669/14A 2001-12-10 2001-12-10 Method for limitation of complications and adverse symptoms in treatment of tuberculosis RU2217137C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2001133669/14A RU2217137C2 (en) 2001-12-10 2001-12-10 Method for limitation of complications and adverse symptoms in treatment of tuberculosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2001133669/14A RU2217137C2 (en) 2001-12-10 2001-12-10 Method for limitation of complications and adverse symptoms in treatment of tuberculosis

Publications (2)

Publication Number Publication Date
RU2001133669A true RU2001133669A (en) 2003-11-20
RU2217137C2 RU2217137C2 (en) 2003-11-27

Family

ID=32027114

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001133669/14A RU2217137C2 (en) 2001-12-10 2001-12-10 Method for limitation of complications and adverse symptoms in treatment of tuberculosis

Country Status (1)

Country Link
RU (1) RU2217137C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2597788C1 (en) * 2015-08-18 2016-09-20 федеральное государственное бюджетное учреждение высшего профессионального образования "Воронежский государственный университет" (ФГБУ ВПО ВГУ) Method for prevention of complications induced by isoniazid

Similar Documents

Publication Publication Date Title
GEP20043354B (en) Therapeutic Formulation for Administering Tolterodine with Controlled Release
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
RU95113492A (en) THERAPEUTIC COMBINATION CONTAINING THE HUMAN INTERFERON, ITS APPLICATION, PHARMACEUTICAL DRUG, PACKAGING AND METHOD OF TREATMENT
RU2003119460A (en) APPLICATION OF PEG-INTERFERON-A (PEG-INF-A) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C
HU9201700D0 (en) Oral preparations for treating internal inflammations and process for its production
BR0011286A (en) Pharmaceutical preparation with the active substance diamorphine and its use in a process to treat opium addiction
JP2002528502A5 (en)
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
JP2003503453A5 (en) Synergistic composition comprising gabapentin and pregabalin
RU2001133669A (en) A way to limit complications and side effects in the treatment of tuberculosis
CA2419077A1 (en) A method of treating a systemic disease
EE200200695A (en) (-) - 5- (3-Chlorophenyl) -alpha- (4-chlorophenyl) -alpha- (1-methyl-1H-imidazol-5-yl) tetrazolo [1,5-a] quinazoline-7-methanamine, a process for its preparation and use, a pharmaceutical composition and a method for its preparation
HK1016408A1 (en) Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis
WO2002007760A3 (en) Therapeutic agent against aids comprising anti hiv goat antibody
RU2000110676A (en) METHOD FOR CONSERVATIVE TREATMENT OF URETHRIC STRICTURES
RU2003136156A (en) PHARMACEUTICAL COMBINATION COMPRISING EITHER (S) -2-ethoxy-3- [4- (2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid or 3- {4- [2- (4-TRETBUTOKSIKARBONILAMINOFENIL) ethoxy] Phenyl} - (S) -ethoxypropionic acid and insulin
WO2002030955A3 (en) Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use
RU96117561A (en) METHOD OF TREATING TOXICOMANIA
RU2001113054A (en) A method for the treatment of postpartum acute purulent-catarrhal endometritis of cows
RU97116119A (en) DRUG FOR THE TREATMENT OF ANIMAL PYROPLASMIDOSIS AND METHOD OF ITS APPLICATION
RU2002105074A (en) METHOD FOR TREATING AND PREVENTING THE DEVELOPMENT OF HYPERTROPHIC AND KELOID SCARS
WO2001028541A3 (en) Composition comprising sildenafil and l-arginine
WO2001039760A3 (en) Method of treating batten disease
RU99112967A (en) METHOD FOR TREATMENT AND PREVENTION OF PIG DYSENTERY
Swies et al. Thrombolytic and Hypotensive Properties of Kallikrein in Anaesthetized Cats